| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC4239 | Prexasertib Monolactate Monohydrate | Novel inhibitor of checkpoint kinase 1 (CHK1) |
|
| DCC4240 | Pridopidine Hydrochloride | Inducer of Functional Neurorestoration Via the Sigma-1 Receptor |
|
| DCC4241 | prmt3 Inhibitor 1 | Allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) |
|
| DCC4242 | prmt3 Inhibitor 14u | Potent and selective inhibitor of protein arginine methyltransferase 3 (PRMT3) |
|
| DCC4243 | Prmt4-in-1 | Novel potent and selective inhibitor of PRMT4 (also known as CARM1) |
|
| DCC4244 | Prmt5-in-4b14 | Novel potent PRMT5 inhibitor, exhibiting potent anti-proliferative activity against a panel of leukemia and lymphoma cells |
|
| DCC4245 | Prmt5-in-c17 Featured | Novel potent, selective, and cell active protein arginine methyltransferase 5 (PRMT5) inhibitor |
|
| DCC4246 | Prmts Inhibitor A36 | Potent inhibitor of protein arginine methyltransferases (PRMTs) |
|
| DCC4247 | Prmts Inhibitor A9 | Potent inhibitor of protein arginine methyltransferases (PRMTs) |
|
| DCC4248 | Prn1008 | Novel, Reversible Covalent BTK Inhibitor for Rheumatoid Arthritis |
|
| DCC4249 | Prn1126 | Novel reversible covalent selective LMP7 inhibitor |
|
| DCC4250 | pr-nhp5g | Antagonist at the NR1/NR2A subtype but an agonist at the NR1/NR2D subtype |
|
| DCC4251 | Probimane | Potent inhibitor of tumor metastasis, inhibiting calmodulin, sialic acid, lipoperoxidation, fibrinogen, cell-movement and the cell-cycle arrest |
|
| DCC4252 | Procaspase-8 Inhibitor 63-r | Novel selective procaspase-8 (Pro-C8) Inhibitor covalently binding the zymogen, or inactive precursor (pro-form), of caspase-8, but not other caspases |
|
| DCC4253 | Pro-nbdhex | Prodrug of NBDHEX, selectively inhibiting glutathione transferase (GST P1-1) with better water solubility, and more potent anticancer activities |
|
| DCC4254 | Protac 14a | Novel potent cereblon degrader with DC50 of 200 nM, and 64% protein degradation, as quantified by western blot |
|
| DCC4256 | Protac Cp17 | Novel highly potent degrader against EGFRL858R/T790M and EGFRdel19, reaching the lowest DC 50 values among all reported EGFR-targeting PROTACs |
|
| DCC4257 | Protac D9a-2 | Novel SLC-targeting chimeric degrader, targeting SLC9A1 and other SLC9 family members, effectively impairing pH homeostasis and differentially killing cancer cell lines |
|
| DCC4258 | Protac Degrader Pp-c8 | Novel noncovalent CDK12/13 dual inhibitor, inducing potent and selective CDK12-CycK degradation without affecting CDK13, suppressing DDR-associated genes and induced synthetic lethality with Olaparib |
|
| DCC4259 | Protac Hl-8 | Novel PI3K degrader, showing a significant and complete degradation effect on PI3K kinase at a concentration of 10 μM within 8 h |
|
| DCC4260 | Protac Nr-7h | Novel potent and selective p38α and p38β degrader |
|
| DCC4261 | Protac P22a | Novel degrader of HMGCR protein, potently blocking cholesterol biosynthesis with less compensatory upregulation of HMGCR |
|
| DCC4262 | Protac P3 | Novel potent epidermal growth factor receptor (EGFR) degrader, inducing EGFRdel19 and EGFRL858R/T790M degradation with DC50 values of 0.51 and 126 nM, showing potent anti-proliferative activity against HCC827 and H1975 cell lines with IC50 values of 0.83 |
|
| DCC4263 | Protac(h-pgds)-1 | Novel potent degrader of H-PGDS protein via the ubiquitin-proteasome system and in the suppression of prostaglandin D2 (PGD2) production |
|
| DCC4264 | Protac_erralpha | Proteolysis targeting chimeras (PROTAC), providing broad tissue distribution and knockdown of the targeted ERRalpha protein in tumor xenografts |
|
| DCC4265 | Protac_ripk2 | Proteolysis targeting chimeras (PROTAC), providing broad tissue distribution and knockdown of the targeted RIPK2 protein in tumor xenografts |
|
| DCC4266 | Protac-12 | Novel SirReal-based PROTAC, inducing isotype-selective Sirt2 degradation, resulting in the hyperacetylation of the microtubule network coupled with enhanced process elongation |
|
| DCC4267 | Protac-3 (fak) | Novel selective and potent Fak degrader |
|
| DCC4268 | Protac-6c | The most potent and selective ERRα degrader |
|
| DCC4269 | Protac-i | Novel PROTAC, targeting steroid hormone receptors for ubiquitination and degradation |
|
